Founded in June 2021 in Shanghai, China, Brise Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering multi-modality therapeutics to transform the treatment landscape for debilitating pain conditions. The company’s mission is to develop innovative and highly differentiated treatments, with the aim to systematically improve pain management and quality of life for patients living with migraine, nociceptive, neuropathic, and nociplastic pain. Brise Pharma was originally formed by a group of veterans with an average of over 15 years extensive experience in drug R&D with global perspective, ranging from preclinical study, clinical development to financing, investment and company operations.